trending Market Intelligence /marketintelligence/en/news-insights/trending/gmjqb-finiidrulgaobgeg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Bristol-Myers Squibb's lung cancer drug shows better response against rival

IFRS 9: Time is Running Out for Insurance Companies to Comply

5 Quant Research Traps to Avoid

Wind Power by the Numbers: U.S., Canada and Mexico

Measuring The Wireline Digital Divide In The US


Bristol-Myers Squibb's lung cancer drug shows better response against rival

New data from Bristol-Myers Squibb's phase three clinical trial of Opdivo indicates better response times in treating non-small cell lung cancer when compared to rival Sanofi SA's docetaxel.

Bristol-Myers said Oct. 9 that Opdivo provided better preservation of health status, health-related quality of life and symptom control under the clinical trials as assessed by the EuroQoL-5 dimensions visual analog scale and the lung cancer symptom score.

More notably, the median duration of response with Opdivo was more than three times that observed with docetaxel which is marketed under the Taxotere brand name.